<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Neurology: Alzheimer Disease Topic Collection</title>
    <link>http://archneur.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 17 Jun 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Mon, 17 Jun 2013 16:44:02 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archneur.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archneur.jamanetwork.com</webMaster>
    <item>
      <title>Dissociable Effects of Alzheimer Disease and White Matter Hyperintensities on Brain Metabolism Alzheimer Disease and White Matter Hyperintensities </title>
      <link>http://archneur.jamanetwork.com/article.aspx?articleID=1697442</link>
      <pubDate>Mon, 17 Jun 2013 00:00:00 GMT</pubDate>
      <author>Haight TJ, Landau SM, Carmichael O, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;Cerebrovascular disease and Alzheimer disease (AD) frequently co-occur and seem to act through different pathways in producing dementia.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To examine cerebrovascular disease and AD markers in relation to brain glucose metabolism in patients with mild cognitive impairment.&lt;div class="boxTitle"&gt;Design and Setting&lt;/div&gt;Cohort study among the Alzheimer Disease Neuroimaging Initiative clinical sites in the United States and Canada.&lt;div class="boxTitle"&gt;Participants&lt;/div&gt;Two hundred three patients having amnestic mild cognitive impairment (74 of whom converted to AD) with serial imaging during a 3-year follow-up period.&lt;div class="boxTitle"&gt;Main Outcomes and Measures&lt;/div&gt;Quantified white matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid β-amyloid represented AD pathology. Brain glucose metabolism in temporoparietal and frontal brain regions was measured using positron emission tomography with fluorodeoxyglucose F18.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;In converters, greater WMHs were associated with decreased frontal metabolism (−0.048; 95% CI, −0.067 to −0.029) but not temporoparietal metabolism (0.010; 95% CI, −0.010 to 0.030). Greater cerebrospinal fluid β-amyloid (per 10-pg/mL increase) was associated with increased temporoparietal metabolism (0.005; 95% CI, 0.000-0.010) but not frontal metabolism (0.002; 95% CI, −0.004 to 0.007) in the same patients. In nonconverters, similar relationships were observed except for a positive association of greater WMHs with increased temporoparietal metabolism (0.051; 95% CI, 0.027-0.076).&lt;div class="boxTitle"&gt;Conclusions and Relevance&lt;/div&gt;The dissociation of WMHs and cerebrospinal fluid β-amyloid in relation to regional glucose metabolism suggests that these pathologic conditions operate through different and independent pathways in AD that reflect dysfunction in different brain systems. The positive association of greater WMHs with temporoparietal metabolism suggests that these pathologic processes do not co-occur in nonconverters.&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">1</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">8</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamaneurol.2013.1878</prism:doi>
      <guid>http://archneur.jamanetwork.com/article.aspx?articleID=1697442</guid>
    </item>
  </channel>
</rss>